Table 1.
Diagnosing contrast-enhancing lesions: Summary of literature results.
| Study (n) | Group (n) | Mean rCBV | Mean PSR (%) | rCBV threshold (Sn%; Sp%) | PSR threshold (%) (Sn%; Sp%) | Comments | Level of evidenceb |
|---|---|---|---|---|---|---|---|
| Hartmann 2003 (24) | GBM (12) | 4.99a | NA | Not provided | NA | Retrospective. No cutoffs, sensitivities or specificities provided. | 4 |
| PCNSL (12) | 1.29a | NA | |||||
| Cha 2007 (43) | GBM (27) | NA | 80.9a | NA | 66 (67; 100) | Retrospective. Some cases not histopathologically confirmed. | 4 |
| MET (16) | NA | 62.5a | |||||
| Liao 2009 (20) | HGG (11) | 4.86a | 93a | Not provided | Not provided | Retrospective. No cutoffs, sensitivities or specificities provided. | 4 |
| PCNSL (9) | 1.72a | 175a | |||||
| Mangla 2011 (66) | GBM (22) | 4.72a | 87a | Not provided | 94 (PCNSL vs. other) (100; 69) 75 (MET vs. other) (100; 83) | Retrospective. Some cases not histopathologically confirmed. | 4 |
| PCNSL (22) | 2.43a | 158a | |||||
| MET (22) | 2.93a | 55a | |||||
| Xing 2013 (38) | HGG (26) | 5.05a | 68a | 2.56 (96.2; 90) | 89 (100; 88.5) | Retrospective | 4 |
| PCNSL (12) | 1.69a | 137a | |||||
| Toh 2013 (35) | GBM (20) | 5.47a | NA | 3.01 (90; 93.3) | NA | Retrospective | 4 |
| PCNSL (15) | 2.28a | NA |
ap < 0.05.
bSee Appendix A.
GBM: glioblastoma; HGG: high-grade glioma; MET: metastasis; NA: not studied; PCNSL: primary central nervous system lymphoma; PSR: percentage of signal intensity recovery; rCBV: relative cerebral blood volume; Sn: sensitivity; Sp: specificity; vs.: versus